Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LBPHNASDAQ:LNTHNYSE:QGENNASDAQ:ROIV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLBPHLongboard Pharmaceuticals$59.98$59.88$27.35▼$60.03$2.34B11.29 million shsN/ALNTHLantheus$79.42-3.0%$83.94$73.11▼$126.89$5.66B0.121.01 million shs931,757 shsQGENQiagen$48.19+0.3%$44.47$37.63▼$49.30$10.68B0.681.19 million shs1.01 million shsROIVRoivant Sciences$10.94-2.9%$11.14$8.73▼$13.06$7.66B1.155.66 million shs14.00 million shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLBPHLongboard Pharmaceuticals0.00%0.00%0.00%0.00%+93.98%LNTHLantheus-2.98%-1.89%+5.18%-18.48%-0.72%QGENQiagen+0.25%+2.02%+6.78%+20.29%+23.21%ROIVRoivant Sciences-2.93%-5.20%-0.36%+8.53%+1.02%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationLBPHLongboard Pharmaceuticals0.1636 of 5 stars1.20.00.00.00.61.70.0LNTHLantheus4.3359 of 5 stars3.51.00.04.21.62.51.9QGENQiagen3.7472 of 5 stars1.25.00.84.52.01.71.3ROIVRoivant Sciences2.0945 of 5 stars3.51.00.00.02.72.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLBPHLongboard Pharmaceuticals 2.38Hold$63.005.04% UpsideLNTHLantheus 3.00Buy$130.5064.32% UpsideQGENQiagen 2.30Hold$49.402.51% UpsideROIVRoivant Sciences 3.00Buy$17.5059.96% UpsideCurrent Analyst Ratings BreakdownLatest LBPH, QGEN, ROIV, and LNTH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/26/2025QGENQiagenBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$50.00 ➝ $53.006/24/2025QGENQiagenBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$55.006/23/2025LNTHLantheusB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$122.00 ➝ $109.006/18/2025ROIVRoivant SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.005/28/2025ROIVRoivant SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.005/8/2025LNTHLantheusTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$127.00 ➝ $117.004/21/2025QGENQiagenRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$42.00 ➝ $43.004/21/2025ROIVRoivant SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.004/4/2025QGENQiagenRedburn AtlanticSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLBPHLongboard PharmaceuticalsN/AN/AN/AN/A$1.67 per shareN/ALNTHLantheus$1.53B3.58$6.88 per share11.54$15.65 per share5.07QGENQiagen$1.98B5.42$3.21 per share14.99$16.05 per share3.00ROIVRoivant Sciences$29.05M256.01N/AN/A$7.45 per share1.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLBPHLongboard Pharmaceuticals-$54.42M-$2.23N/AN/AN/AN/A-33.03%-30.90%N/ALNTHLantheus$312.44M$3.5222.5612.59N/A16.55%36.99%20.55%7/30/2025 (Estimated)QGENQiagen$83.59M$0.40120.8319.592.454.68%14.61%8.80%7/30/2025 (Estimated)ROIVRoivant Sciences-$171.98M-$0.25N/AN/AN/A-225.71%-14.76%-13.69%8/6/2025 (Estimated)Latest LBPH, QGEN, ROIV, and LNTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/30/2025Q2 2025LNTHLantheus$1.65N/AN/AN/A$389.69 millionN/A7/30/2025Q2 2025QGENQiagen$0.60N/AN/AN/A$523.97 millionN/A5/29/2025Q4 2025ROIVRoivant Sciences-$0.16-$0.31-$0.15-$0.29$62.17 million$7.57 million5/7/2025Q1 2025LNTHLantheus$1.64$1.53-$0.11$1.02$377.37 million$372.76 million5/7/2025Q1 2025QGENQiagen$0.50$0.55+$0.05$0.41$465.66 million$483.46 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLBPHLongboard PharmaceuticalsN/AN/AN/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/AQGENQiagenN/AN/AN/AN/AN/AROIVRoivant SciencesN/AN/AN/AN/AN/ALatest LBPH, QGEN, ROIV, and LNTH DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date7/1/2025QGENQiagen$0.250.52%7/2/20257/3/20257/10/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLBPHLongboard PharmaceuticalsN/A15.9715.97LNTHLantheus0.495.745.46QGENQiagen0.403.372.83ROIVRoivant SciencesN/A33.4733.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLBPHLongboard Pharmaceuticals63.28%LNTHLantheus99.06%QGENQiagen70.00%ROIVRoivant Sciences64.76%Insider OwnershipCompanyInsider OwnershipLBPHLongboard Pharmaceuticals4.64%LNTHLantheus2.00%QGENQiagen9.00%ROIVRoivant Sciences7.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLBPHLongboard Pharmaceuticals2039.05 million37.23 millionOptionableLNTHLantheus70069.19 million67.80 millionOptionableQGENQiagen5,765222.29 million202.29 millionOptionableROIVRoivant Sciences860679.81 million626.10 millionOptionableLBPH, QGEN, ROIV, and LNTH HeadlinesRecent News About These Companies'Just the beginning': Vivek Ramaswamy breaks record in raising fund for Guv election campaign, $8.5 million in five monthsJune 28, 2025 | msn.comRoivant Sciences’ president Venker sells $1.15 million in sharesJune 26, 2025 | investing.comInvestors Buy Large Volume of Roivant Sciences Call Options (NASDAQ:ROIV)June 26, 2025 | marketbeat.comInsider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) Major Shareholder Sells $6,612,500.22 in StockJune 26, 2025 | americanbankingnews.comVivek Ramaswamy Sells 565,266 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) StockJune 26, 2025 | americanbankingnews.comPenn Davis Mcfarland Inc. Has $17.23 Million Stock Position in Roivant Sciences Ltd. (NASDAQ:ROIV)June 25, 2025 | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $1,145,000.00 in StockJune 25, 2025 | insidertrades.comRoivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker Sells 100,000 SharesJune 24, 2025 | marketbeat.comRoivant Sciences Subsidiary Pulmovant Publishes Positive Phase 1 Data for Inhaled PH Treatment MosliciguatJune 24, 2025 | msn.comInsider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) Major Shareholder Sells 565,266 Shares of StockJune 24, 2025 | insidertrades.comRoivant Sciences (ROIV) : Ramaswamy vend des actions pour 13 millionsJune 23, 2025 | fr.investing.comRoivant Sciences Ltd. (NASDAQ:ROIV) Major Shareholder Sells $6,472,295.70 in StockJune 23, 2025 | marketbeat.comInsider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) Major Shareholder Sells 577,007 Shares of StockJune 23, 2025 | marketbeat.comAssenagon Asset Management S.A. Takes $570,000 Position in Roivant Sciences Ltd. (NASDAQ:ROIV)June 20, 2025 | marketbeat.comRoivant Sciences (NASDAQ:ROIV) Shares Up 5.4% - What's Next?June 18, 2025 | marketbeat.comHC Wainwright Reiterates Buy Rating for Roivant Sciences (NASDAQ:ROIV)June 18, 2025 | marketbeat.comPulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical PharmacokineticsJune 16, 2025 | globenewswire.comRoivant Sciences à la conférence Goldman Sachs : focus sur l’exécution stratégiqueJune 10, 2025 | fr.investing.comRoivant Sciences Ltd. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 04:00 PMJune 10, 2025 | zonebourse.comZGAMMA Investing LLC Has $6.49 Million Stock Position in Roivant Sciences Ltd. (NASDAQ:ROIV)June 10, 2025 | marketbeat.comRoivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in DermatomyositisJune 9, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLBPH, QGEN, ROIV, and LNTH Company DescriptionsLongboard Pharmaceuticals NASDAQ:LBPHLongboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.Lantheus NASDAQ:LNTH$79.42 -2.44 (-2.98%) Closing price 07/1/2025 04:00 PM EasternExtended Trading$80.50 +1.08 (+1.36%) As of 08:23 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Qiagen NYSE:QGEN$48.19 +0.13 (+0.27%) Closing price 07/1/2025 03:59 PM EasternExtended Trading$47.73 -0.46 (-0.95%) As of 08:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.Roivant Sciences NASDAQ:ROIV$10.94 -0.33 (-2.93%) Closing price 07/1/2025 04:00 PM EasternExtended Trading$10.93 -0.01 (-0.09%) As of 08:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High 2 Under the Radar Space & Defense Stocks With Huge Potential Why Realty Income’s 5.59% Yield Makes It a Must-Buy REIT Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Forget IBM: Accenture’s AI Momentum Is Your Next Buy Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
